Question · Q4 2019
Adam Walsh from Stifel, Nicolaus & Company, Inc. asked about the specific clinical thresholds for announcing PTG-300 data, whether a twice-weekly dosing regimen is being considered for indications other than beta-thalassemia, and for comments on competition from Morphic's oral alpha-4-beta-7 integrin competitor.
Answer
CFO Donald Kalkofen and President and CEO Dinesh Patel explained that the threshold for announcing PTG-300 data is reaching a point of certainty that warrants moving into a registration program, with the primary goal of selecting the first pivotal indication in 2020. Regarding dosing, they noted the study design allows for flexibility, but the goal is always the lowest, least frequent dose possible. Mr. Patel acknowledged awareness of competitors like Morphic but declined to comment on their programs.